相关实验视频
Updated: Jul 8, 2025

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
在扩散性大B细胞淋巴瘤中进行抗体和免疫治疗
Allison Barraclough1, Eliza A Hawkes2
1Fiona Stanley Hospital, Perth, Australia; University of Melbourne, Melbourne, Victoria, Australia.
扩散性大B细胞淋巴瘤 (DLBCL) 治疗与抗体疗法和免疫疗法取得了重大进展,改善了许多患者的生存率. 本综述探讨了这些创新和DLBCL治疗的未来方向.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种常见且复杂的B细胞恶性瘤.
- 虽然许多患者通过初始免疫化学疗法获得治愈,但耐火性疾病的预后不佳.
结论:
- 在过去的40年里,抗体疗法和免疫疗法代表了DLBCL的主要治疗进展.
- 基于抗体的新型策略的持续开发为管理DLBCL提供了有希望的未来方向.
更多相关视频
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
相关概念视频
Tumor Immunotherapy
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...